class action lawsuit

Kyndryl faces securities class action after disclosing internal control weaknesses, CFO/General Counsel departures, and 55% stock decline. Lead plaintiff deadline is April 13, 2026.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

CoreWeave faces securities class action alleging material misrepresentations about capacity and concealed data center supplier risks. Lead plaintiff applications due March 13, 2026.

BellRing Brands faces securities lawsuit for failing to disclose material information about business challenges between November 2024 and August 2025, leading to significant stock declines.

Rosen Law Firm sues Picard Medical for alleged fraudulent stock promotion and concealment of adverse information. Investors must act before April 13, 2026 deadline to become lead plaintiff.

Varonis Systems faces class action lawsuit after stock plunged 48.67% on October 29 following missed revenue projections and weak customer conversions disclosure.

BellRing Brands faces securities lawsuit alleging false statements about financial performance and growth. Class action covers November 2024 through August 2025 for affected investors.

Paysafe shareholders can join class action lawsuit until April 7, 2026, alleging the company made false statements and failed to disclose material issues affecting investors.

Class action lawsuit filed against Klarna for allegedly making false statements about risks associated with loan losses in its September 2025 IPO.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

Kyndryl Holdings faces securities lawsuit alleging false financial statements and inadequate internal controls, with shareholders from August 2024-February 2026 eligible to join the class action.

Gross Law Firm sues TCPC over false valuation disclosures. Shareholders must register claims by April 6, 2026.

PayPal faces class action lawsuit for allegedly issuing false revenue guidance and missing 2027 targets, prompting CEO departure and 20% stock decline.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Class action lawsuits filed against BlackRock TCP Capital and Plug Power for alleged material misrepresentations regarding financial information and business operations.

PayPal faces class action lawsuit alleging misleading revenue guidance. Stock dropped 20% after weak Q4 results and withdrawn 2027 guidance; CEO transition announced.

Kyndryl faces securities fraud lawsuit over alleged misrepresentations. Stock plunged 55% after February disclosure of internal control weaknesses. Investors have until April 13 to join class action.

CoreWeave faces securities fraud lawsuit alleging false statements about operational capabilities and supplier risks. March 13, 2026 deadline set for investors to claim lead plaintiff status.

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.